




EMLc
Codes ATC: N07AA01

| | |
|------------------------------|---|
| Indication | Myasthenia gravis Code ICD11: 8C70.Z |
| INN | Neostigmine bromide |
| Type de médicament | Chemical agent |
| Type de liste | Liste de base (EML) (EMLc) |
| Formulations | Oral > Solid: 15 mg (neostigmine bromide) Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) |
| Historique des statuts LME | Ajouté pour la première fois en 1977 (TRS 615) Modifié en 1979 (TRS 641) Modifié en 1989 (TRS 796) Modifié en 2003 (TRS 920) Modifié en 2007 (TRS 950) |
| Sexe | Tous |
| Âge | Aussi recommandé pour les enfants |
| Équivalence thérapeutique | La recommandation concerne ce médicament spécifique |
| Renseignements sur le brevet | Patents have expired in most jurisdictions Lire la suite sur les brevets.  |
| Wikipédia | Neostigmine  |
| DrugBank | Neostigmine  |

Résumé des preuves et recommandation du comité d'experts

The EMLc Subcommittee noted that neostigmine metilsulfate injection was the preferred agent for the reversal of non-depolarising muscle block and endorsed neostigmine injection for inclusion in the EMLc. While neostigmine bromide tablets are licensed for use in infants and children for the treatment of myasthenia gravis, the Subcommittee noted that pyridostigmine has fewer cholinergic adverse effects and is now regarded as the first-line drug treatment for myasthenia gravis. The Subcommittee endorsed neostigmine (injection and tablet forms) and pyridostigmine (injection and tablet forms) for inclusion in the EMLc, with the latter retained in the Complementary List.

